Using the rich genomic annotation of the TCGA cohort, we next examined association of ZBTB38 expression levels with frequent alterations found in prostate cancer such as mutation or copy number aberration of SPOP, TP53 and PTEN. We did not observe a correlation between ZBTB38 expression levels and TP53 and PTEN loss or mutation (Table S2 and S3). The gene discussed is ZBTB38; the disease is prostate cancer.